Home › Kanser sa Bato (Renal Cell Carcinoma) › South Carolina
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa South Carolina
12 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa South Carolina.
Mga Lungsod sa South Carolina
Opisyal na teksto ng pag-aaral (English)
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 South Carolina Site, Myrtle Beach
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07300241A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Prisma Health Cancer Institute, Greenville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07419841Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AnMed Health Cancer Center, Anderson
- Prisma Health Richland Hospital, Columbia
- McLeod Regional Medical Center, Florence
- at 12 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #9, Myrtle Beach
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Medical University of South Carolina, Charleston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- MUSC Hollings Cancer Center, Charleston
- Carolina Urologic Research Center, LLC, Myrtle Beach
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07293351Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Medical University of South Carolina, Charleston
- Self Regional Healthcare, Greenwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Grand Strand Medical Center, Myrtle Beach
- Carolina Urologic Research Center, LLC, Myrtle Beach
- Parkway Surgery Center, Myrtle Beach
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Carolina Urologic Research Center, Myrtle Beach
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- MUSC Hollings Cancer Center, Charleston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06750185Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- at 10 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Medical University of South Carolina, Charleston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04510597Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.